- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J0517
    - J2182
    - J2786
    - J3590
  conditions:
    all_of:
    - dx_in_value_set: vs_asthma_severe_2025_09
    - has_flag: step_5_therapy_failed
    - has_flag: ige_elevated_or_eosinophilia
    - min_age: 12
    none_of:
    - dx_in_value_set: vs_active_malignancy_2025_09
    - has_flag: immunodeficiency
  logic:
    outcome: PA_REQUIRED
    notes: Asthma biologics require severe asthma with failed step 5 therapy and elevated
      IgE or eosinophils
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_asthma_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_1f750dcb89b0
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J0517
  conditions:
    all_of:
    - dx_in_value_set: vs_asthma_allergic_2025_09
    - has_flag: ige_level_30_700
    - has_flag: positive_allergen_testing
    - has_flag: inhaled_corticosteroid_failed
    none_of:
    - has_flag: omalizumab_within_16_weeks
  logic:
    outcome: PA_REQUIRED
    notes: Omalizumab requires allergic asthma with IgE 30-700 IU/mL and positive
      allergen testing
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_asthma_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_2b843eda6d6e
- type: PRIOR_AUTH
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J2182
  conditions:
    all_of:
    - dx_in_value_set: vs_asthma_eosinophilic_2025_09
    - has_flag: eosinophil_count_300_plus
    - has_flag: exacerbations_2_plus_per_year
    - has_flag: high_dose_ics_laba_failed
    none_of:
    - dx_in_value_set: vs_parasitic_infection_2025_09
  logic:
    outcome: PA_REQUIRED
    notes: "Mepolizumab requires eosinophilic asthma with \u2265300 eosinophils and\
      \ \u22652 exacerbations/year"
  precedence: 90
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_asthma_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_2c63c2c7f230
- type: EDIT
  scope:
    carrier_id: crr_7f9b2e1a2b3c
    lob: commercial_fully_insured
    state: CA
    plan_type: ''
    market: ''
  service_ref:
    cpt:
    - J0517
    - J2182
    - J2786
    - J3590
  conditions:
    all_of:
    - dx_in_value_set: vs_asthma_mild_2025_09
    none_of:
    - has_flag: controller_therapy_failed
    - has_flag: frequent_exacerbations
  logic:
    outcome: DENY
    notes: Asthma biologics not indicated for mild asthma without failed controller
      therapy
  precedence: 95
  effective_start: '2025-01-01'
  effective_end: '2025-12-31'
  _meta:
    source: sources/2025-09/unitedhealth/uhc_asthma_biologics_2025.pdf
    last_verified_at: '2025-09-11'
  id: rule_a713b8fb8375
